Gluten  Free
 Indy
  • Home
  • The Gluten-Free Diet
  • Oats
  • Cross-Contamination
  • Recipes
  • Restaurant Menus
  • Newsletters
  • Symptoms
  • Diagnosis
  • Family Risk
  • Gluten-Free and not well??
  • Arsenic in rice
  • You should know that...
  • Diabetes and CD
  • Women's Health
  • Children's Resources
  • College
  • Online References
  • Find a Doctor

AN-PEP Enzyme
​

AN-PEP (aspergillus niger prolyl endopeptidase), new dietary supplement, is available, has been studied and (unlike other enzyme supplements on the market), shown to break down gluten in the stomach.  However, it has not gone through clinical trials and been proven to help those with Celiac Disease or Gluten Sensitivity.  In fact, one study failed to show an effect in people with CD, although the study authors believe that was due to the study design (see below for further information).   AN-PEP is by no means a substitute for the Gluten-Free diet. It does not completely degrade gluten  It is intended only to help with cross-contamination, and there is reason to believe that it would be effective for that purpose (see research articles below).  ​​

Note from the editor:  I personally tried one of these supplements and the very first pill caused nausea, so I won't be able to take it again.  However, it is not unusual for me to be sensitive to medication, so your experience may be different.  If you have a very sensitive stomach, this product may not be for you.
​
The scientific name of the enzyme is Aspergillus Niger prolyl endoprotease, or AN-PEP.
​

The trade name is Tolerase G
​
  Here is a video from the manufacturer.
​ 
Tolerase G is available in a number of products, including
:
​GliadinX
 GlutnGo™ (GlutnGo is on Amazon*)
 SpectraZyme® Gluten Digest
Gluten Rid


See this article:  Are Enzymes Safe for the Celiac Disease Community? Researchers Set the Record Straight

Research on AN-PEP (Tolerase G)
2017:  ​Randomized clinical trial: Effective gluten degradation by Aspergillus niger-derived enzyme in a complex meal setting
2017:  A unique enzyme could be a game-changer for gluten-sensitive patients

2015:  Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers.
​
2015:  Letter (regarding above study) Gluten digestion in the stomach and duodenum by Aspergillus-derived enzyme - things              to ponder

2015:  Author's reply to Letter: gluten digestion in the stomach and duodenum by Aspergillus niger-derived enzyme – things to            ponder.

2015:  Influence of dietary components on Aspergillus niger prolyl endoprotease mediated gluten degradation.
           From the abstract:  
  • AN-PEP optimal dosage was 20 proline protease units (PPU) per gram of gluten.
  • The addition of a carbonated drink strongly enhanced AN-PEP activity because of its acidifying effect.
  • Fat did not affect gluten degradation by AN-PEP.
  • The presence of food proteins slowed down gluten detoxification.
  • Raw gluten was degraded more efficiently by AN-PEP than baked gluten.
  • Therefore, meal composition influences the amount of AN-PEP needed for gluten elimination. ​

2013:  Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study
           This study failed to prove an effect, but the authors believe the study design may have contributed to that.   From the                 Discussion section:  "the primary aim of the study was not met as the placebo arm did not show any deterioration after
           2 wk of gluten consumption. With hindsight, the study should possibly have been designed for a much longer period of               time with many more patients".


2008:  Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease.

2006:  Highly efficient gluten degradation with a newly identified prolyl endoprotease: implications for celiac disease.
​
Other Enzymes in Development
2018:  Is an enzyme supplement for Celiac Disease finally on the cards?
KumaMax

2017:  Latiglutenase, also known as IMGX003
 and formerly as ALV-003 has recently completed Phase IIb trials with mixed results: 
  • 2017:  No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease
  • ​2017:  Disappointing Results in Celiac Disease Drug Trial But Future Hopeful

2015:  Ineffective Degradation of Immunogenic Gluten Epitopes by Currently Available Digestive Enzyme Supplements
           Note:  This title does not refer to AN-PEP.  Five other enzyme supplements, containing DPPIV and on the US market in            2012, were tested and shown to be ineffective).  

​2009:  A Food-Grade Enzyme Preparation with Modest Gluten Detoxification Properties​

​* This is an Amazon affiliate link.  If you go to Amazon from this link and then buy something, a small percentage of the sale goes to the support group at no extra cost to you.  If you do not want to use the affiliate link, you can go to Amazon a different way and just search for the product.
About Us
Contact Us